In recent years, Chinese innovative pharmaceutical companies have significantly accelerated their internationalization in the field of business development (BD). According to the latest industry data, the total value of outbound licensing deals (License-out) for domestically developed innovative drugs has surpassed $100 billion—a milestone that marks China’s transition from a follower to a peer, and even a leader, in global pharmaceutical innovation. This achievement reflects growing international recognition of China’s drug R&D capabilities and demonstrates the enhanced strength of domestic firms in target discovery, clinical development, and intellectual property strategy. Notable transactions include major collaborations between companies like BeiGene, Innovent Biologics, and Legend Biotech with global pharma giants such as Novartis, Eli Lilly, and Johnson & Johnson. These deals typically follow a structure combining upfront payments, milestone payments, and royalty shares, highlighting strong confidence from international partners in Chinese innovation. As more first-in-class or best-in-class therapies advance onto the global stage, China is poised to play an increasingly central role in the worldwide pharmaceutical ecosystem.
近年来，中国创新药企在生物医药（BD，Business Development）领域的国际化进程显著加速。据最新行业数据显示，国产创新药通过对外授权（License-out）等方式实现的出海交易总金额已突破1000亿美元大关，标志着中国医药创新从‘跟跑’迈向‘并跑’甚至‘领跑’阶段。这一里程碑不仅体现了全球市场对中国原研药物研发能力的认可，也反映出本土企业在靶点发现、临床开发和知识产权布局等方面的综合实力提升。代表性交易包括百济神州、信达生物、传奇生物等企业与国际制药巨头如诺华、礼来、强生等达成的重磅合作。这些合作通常采用‘首付款+里程碑付款+销售分成’的模式，凸显了海外药企对中国创新成果的高度期待。未来，随着更多First-in-Class或Best-in-Class药物走向国际市场，中国有望在全球医药产业链中扮演更加核心的角色。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/588.html